Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

NovaDigm Therapeutics initiates NDV-3A Phase 2a study for reduction of S. aureus in military trainees

NovaDigm Therapeutics, a company developing innovative immuno-therapeutics and preventative vaccines for fungal and bacterial infections, today announced the initiation of a Phase 2a study evaluating NDV-3A for the reduction of Staphylococcus aureus (S. aureus) colonization in a high-risk population of military trainees.

19 Apr 2018

Innovative device shows promise in capturing and releasing circulating tumor cells

For years, bioengineer Yaling Liu has been in pursuit of the deadly tumor cell. Liu has been perfecting a microfluidic device the size of two quarters that has the ability to catch and release circulating tumor cells (CTCs)--cancer cells that circulate in a cancer patient's blood.

19 Apr 2018

New insight may allow researchers to design drugs that improve immune responses to vaccines

Memory T cells are a critical element of our immune system's historical archive. To prevent repeat infections, these cells retain a record of germs they've fought before.

19 Apr 2018

New drug for migraine in the pipeline

According to a pilot study results released yesterday (17th of April 2018), a new drug may help provide relief to people with migraine that is unsuccessfully treated with the currently available drugs.

18 Apr 2018

Two immune checkpoint inhibitors efficiently block leukemia development in preclinical tests

Chronic lymphocytic leukemia is a hematological malignancy that originates in the blood-forming cells of the bone marrow and spreads to other organs through the bloodstream.

17 Apr 2018

SYGNIS AG extends manufacturing capability for Lightning-Link technology

SYGNIS AG, the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced it has extended the manufacturing capability for its Lightning-Link technology, currently marketed under the Expedeon brand, to support scalability and bulk production of antibodies.

16 Apr 2018

SYGNIS AG launches new Universal Lateral Flow Assay kit and files patent application

SYGNIS AG today announced the launch of its Universal Lateral Flow Assay kit, the latest addition to its expanding range of lateral flow assay products and services which are being commercialized under the Expedeon brand name.

16 Apr 2018

SYGNIS AG acquires bioconjugation specialist Expedeon

Expedeon, a specialist provider of bioconjugation products and services, has announced it has been fully acquired by Sygnis AG, for EUR 8 million in cash and 3.5 million in shares.

16 Apr 2018

New award will help research into immune system differences that trigger food allergies

Adora A. Lin, M.D., Ph.D., an attending physician in Children's department of Allergy and Immunology, was awarded $240,000 to improve understanding of how children's immune systems tolerate or react to certain food allergens--sometimes triggering a cascade of side effects that can be fatal.

13 Apr 2018

Research reveals immune suppressive role of soluble antibodies in tumor progression

Wistar researchers have found that soluble antibodies promote tumor progression by inducing accumulation of myeloid-derived suppressor cells (MDSCs) in pre-clinical cancer models. Results were published online in Cancer Immunology Research.

13 Apr 2018

TradeShow Talks with Cyanagen

We are Cyanagen, an Italian company, here at Analytica in hall A3 booth 416. We produce reagents for molecular biology, mainly ECL substrates for Western blot analyzers and fluorescent reagents for several applications.

From Cyanagen Srl 12 Apr 2018

Nanotechnology-based treatment approach shown to be effective in mouse models of lung cancer

The most common type of lung cancer, non-small cell lung cancer (NSCLC), continues to be difficult to treat, with five year survival rates of about 36 percent for stage 3A tumors.

11 Apr 2018

Scripps Florida researchers awarded $2.875 million to destroy common form of leukemia

Christoph Rader, PhD, associate professor at the Florida campus of The Scripps Research Institute, has been awarded a $2.875 million, five-year grant from the National Cancer Institute to develop unique antibody-drug conjugates engineered to eradicate one of the most common forms of leukemia, chronic lymphocytic leukemia

10 Apr 2018

New point-of-care test accelerates diagnosis of Lyme neuroborreliosis

A new research-based point-of-care test has been developed in Finland for detecting the Lyme neuroborreliosis spread by ticks.

5 Apr 2018

TSRI research could lead to new approach for better flu prevention and treatment

This year's flu vaccine has been less effective in protecting people from the most common strain of the virus, compared with recent years. And once people become infected with the flu, there are few good ways to treat it.

3 Apr 2018

Combined treatment prolongs survival in mouse models of malignant mesothelioma

Combined treatment with two cancer immunotherapy drugs - one a novel immune modulator and one that focuses and activates the antitumor immune response - significantly prolonged survival in mouse models of the aggressive cancer malignant mesothelioma.

2 Apr 2018

Salk scientists discover protein that 'turns off' uncontrolled liver cancer growth

Salk Institute scientists, together with researchers from Switzerland's University of Basel and University Hospital Basel, discovered a protein called LHPP that acts as a molecular switch to turn off the uncontrolled growth of cells in liver cancer.

29 Mar 2018

Tiny biochip holds promise for rapid and accurate disease detection

A novel invention by a team of researchers from the National University of Singapore (NUS) holds promise for a faster and cheaper way to diagnose diseases with high accuracy.

29 Mar 2018

New $3.2 million grant funds research to advance promising malaria vaccine

The Global Health Innovative Technology Fund has awarded the University of Florida and partners in the United States and Japan $3.2 million to advance a promising vaccine to prevent transmission of malaria.

29 Mar 2018

Phase I clinical trial of HIV vaccines to begin in the U.S.

A Phase I clinical trial testing the safety of vaccines that might have the potential to prevent HIV infection will begin this month at four sites in the United States, marking the latest step in a three-decade quest at UMass Medical School to harness the power of DNA vaccines in addressing a major global health threat.

28 Mar 2018

Antibody News and Research

Further Reading

NovaDigm Therapeutics initiates NDV-3A Phase 2a study for reduction of S. aureus in military trainees

Innovative device shows promise in capturing and releasing circulating tumor cells

New insight may allow researchers to design drugs that improve immune responses to vaccines

New drug for migraine in the pipeline

Two immune checkpoint inhibitors efficiently block leukemia development in preclinical tests

SYGNIS AG extends manufacturing capability for Lightning-Link technology

SYGNIS AG launches new Universal Lateral Flow Assay kit and files patent application

SYGNIS AG acquires bioconjugation specialist Expedeon

New award will help research into immune system differences that trigger food allergies

Research reveals immune suppressive role of soluble antibodies in tumor progression

TradeShow Talks with Cyanagen

Nanotechnology-based treatment approach shown to be effective in mouse models of lung cancer

Scripps Florida researchers awarded $2.875 million to destroy common form of leukemia

New point-of-care test accelerates diagnosis of Lyme neuroborreliosis

TSRI research could lead to new approach for better flu prevention and treatment

Combined treatment prolongs survival in mouse models of malignant mesothelioma

Salk scientists discover protein that 'turns off' uncontrolled liver cancer growth

Tiny biochip holds promise for rapid and accurate disease detection

New $3.2 million grant funds research to advance promising malaria vaccine

Phase I clinical trial of HIV vaccines to begin in the U.S.

Accelerating therapeutic antibody discovery and development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo